Preclinical Studies of Pf-04849285, An Interferon-α8 Fusion Protein for the Treatment of HCV
- 1 July 2012
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 17 (5) , 869-881
Abstract
Background: This study presents preclinical data of a novel interferon (IFN)-α8 fusion protein, PF-04849285, and compares it with IFN-α2 and pegylated IFN-α2; the latter being the current standard of care for HCV. Methods: The antiviral properties were evaluated in vitro using the HCV replication assay (replicon) and the general encephalomyocarditis virus assay. The binding affinity to both IFNR-subunits was assessed using surface plasmon resonance. Ex vivo experiments using cynomolgus monkey and human blood were used for the evaluation of induction of IFN-inducible biomarkers (interferon inducible protein 10 [IP-10], 2′-5′-oligoadenylate synthetase [OAS2] and interleukin-6 [IL-6]). The molecule was tested intravenously and subcutaneously in cynomolgus monkey in a single dose study for two weeks at 0.01, 1, 5 and 20 mg/kg. Each route and dose combination was given to a single male animal, blood samples were collected for evaluation of biomarkers and pharmacokinetics. The compound was also tested in cynomolgus monkey in a multiple dose study for four weeks, with a twice-a-week dosing prior to a three-week wash-out period for toxicokinetics, pharmacokinetics, and biomarker evaluation at 20, 50 or 100 mg/kg subcutaneously and 20 mg/kg intravenously. Results: The molecule is 10x more potent than the pegylated IFN-α2a, with potency similar to the unmodified IFN-α2a. No unanticipated findings were observed in cynomolgus monkey when dosed up to 20 mg/kg, >10,000-fold margin over the anticipated efficacious human dose. Conclusions: The biomarker and toxicological findings were consistent with a potent IFN molecule. The potency and pharmacokinetic properties of the molecule are consistent with dosing at least twice daily with the potential for monthly dosing.Keywords
This publication has 33 references indexed in Scilit:
- Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3Gastroenterology, 2010
- Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapyAlimentary Pharmacology & Therapeutics, 2010
- Rigid Interferon-α Subtype Responses of Human Plasmacytoid Dendritic CellsJournal of Interferon & Cytokine Research, 2008
- Albinterferon alfa‐2b dosed every two or four weeks in interferon‐naïve patients with genotype 1 chronic hepatitis C†‡Hepatology, 2008
- Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis CNature Biotechnology, 2007
- Directed evolution of gene-shuffled IFN-α molecules with activity profiles tailored for treatment of chronic viral diseasesProceedings of the National Academy of Sciences, 2007
- Ligand-induced Assembling of the Type I Interferon Receptor on Supported Lipid BilayersJournal of Molecular Biology, 2004
- Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activitiesEuropean Journal of Immunology, 1999
- Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNα2 1 1Edited by A. R. FershtJournal of Molecular Biology, 1999
- Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cellsBiochemical and Biophysical Research Communications, 1983